Publications by authors named "Graham Lunn"

Claim this Profile
D
Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion.
G Stuart Cockerill, Richard M Angell, Alexandre Bedernjak, Irina Chuckowree, Ian Fraser, Graham Lunn

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.
Mark D Andrews, Kerry Af Forselles, Kevin Beaumont, Sébastien R G Galan, Paul A Glossop, Graham Lunn

ACS Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of libraries to access new chemical space: applications to CRTH2.
M Abid Masood, Mark Gardner, Kevin Dack, David Winpenny, Graham Lunn

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and biological evaluation of 3-azabicyclo[3.1.0]hexane derivatives as μ opioid ligands.
Graham Lunn, Lee R Roberts, Stephane Content, Douglas J Critcher, Sara Douglas

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.
Susan Cole, Sharan Bagal, Ayman El-Kattan, Katherine Fenner, Tanya Hay, Graham Lunn

Xenobiotica· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a 'magic methyl' giving a 35-fold improvement in binding.
Graham Lunn, Bernard J Banks, Robert Crook, Neil Feeder, Alan Pettman

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis